The Overview
argenx SE announced positive topline results from its Phase 2 study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. The study met its primary endpoint, demonstrating a statistically significant and clinically relevant treatment effect compared to placebo, with a p-value of 0.0176 for the change from baseline in the ratio of villus height–to–crypt depth (Vh:Cd) at day 78. This marks the first clinical readout of FB102 following argenx's acquisition of Forte Biosciences in August 2026. The observed safety profile was consistent with prior studies, and argenx plans to advance FB102 into Phase 3 development, highlighting its potential to address the unmet need in celiac disease, which currently lacks approved therapies.
Knolens Analysis
At a Glance
| Indication | Celiac disease |
| Drug | FB102 |
| Mechanism of Action | CD122 inhibitor |
| Company | argenx SE |
| Trial Phase | Phase 2 |
| Trial Acronym | FB102-301 |
| NCT ID | NCT06982963 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Gastroenterology & Hepatology |
| Primary Endpoint | Change from baseline in the ratio of villus height–to–crypt depth (Vh:Cd) at day 78 versus placebo |
| P-value | 0.0176 |
| Patient Population Size | 126 patients |
| Gluten Challenge Duration | Eight-week oral gluten challenge |
| Regulatory Designation | Fast Track Designation |
| Acquisition Date | August 2026 |
| Other Investigated Indications | Vitiligo, Alopecia areata |
| Comparator | Placebo |
| Randomization Ratio | 2:2:1 |
argenx's FB102 Achieves Positive Phase 2 Topline Results in Celiac Disease
argenx SE announced positive topline results from its Phase 2 study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. The study met its primary endpoint, demonstrating a statistically significant and clinically relevant treatment effect compared to placebo, with a p-value of 0.0176 for the change from baseline in the ratio of villus height–to–crypt depth (Vh:Cd) at day 78. This marks the first clinical readout of FB102 following argenx's acquisition of Forte Biosciences in August 2026. The observed safety profile was consistent with prior studies, and argenx plans to advance FB102 into Phase 3 development, highlighting its potential to address the unmet need in celiac disease, which currently lacks approved therapies.
- The Phase 2 study of FB102 in adults with celiac disease met its primary endpoint, demonstrating a statistically significant and clinically relevant improvement in the ratio of villus height-to-crypt depth (Vh:Cd) at day 78 versus placebo (p=0.0176). This outcome provides the first Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage, even under an intense gluten challenge, addressing a critical need for effective treatments.
- FB102 exhibited a safety profile consistent with prior studies, with no new safety signals identified. Beyond the primary endpoint, broad efficacy measures, including intraepithelial lymphocyte (IEL) density, villus height-to-crypt depth intraepithelial lymphocyte (VCIEL) composite score, and patient symptoms, were all consistent with the primary findings, providing comprehensive evidence of effect across histologic, inflammatory, and clinical measures.
- These positive results strengthen argenx's conviction in FB102's potential, validating CD122 as a promising therapeutic target in celiac disease, where there are currently no approved therapies. The company plans to advance FB102 into Phase 3 development and further explore its broader potential across other immune-mediated diseases, building on its U.S. FDA Fast Track Designation for celiac disease.
Frequently Asked Questions
What are the primary unmet needs in celiac disease management beyond dietary restrictions?
Despite strict adherence to a gluten-free diet, a significant proportion of celiac disease patients experience persistent symptoms, ongoing intestinal damage, or develop refractory celiac disease. These individuals face a substantial burden on their quality of life and remain at risk for long-term complications. Current management offers no pharmacological options to protect against accidental gluten exposure or to effectively heal persistent enteropathy.
How do investigational therapies for celiac disease modulate the immune response to gluten?
Emerging therapies for celiac disease target various points in the pathogenic cascade triggered by gluten. Approaches include gluten degradation enzymes to reduce immunogenic peptides, tight junction modulators to decrease intestinal permeability, and immunomodulators that block specific inflammatory pathways or T-cell activation. These strategies aim to prevent or mitigate the immune-mediated damage to the small intestine.
Which celiac disease patient subgroups are most likely to benefit from novel pharmacological treatments?
Novel pharmacological treatments are particularly relevant for patients who do not achieve full remission on a gluten-free diet, including those with persistent symptoms, ongoing villous atrophy, or refractory celiac disease. Additionally, individuals with a high risk of accidental gluten exposure or those struggling with strict dietary adherence could benefit. These therapies aim to provide additional protection and improve clinical outcomes in these challenging patient populations.
What are the critical clinical endpoints and biomarkers for assessing efficacy in celiac disease drug development?
Key clinical endpoints for celiac disease drug development typically include improvements in patient-reported outcomes such as symptom scores and quality of life measures. Histological healing, assessed by changes in villous height-to-crypt depth ratio or intraepithelial lymphocyte counts, is also crucial. Relevant biomarkers may include serological markers like tissue transglutaminase (tTG) antibodies and deamidated gliadin peptide (DGP) antibodies, as well as inflammatory markers.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
